Hyphens Pharma International - SAC Capital 2024-05-16: Robust Growth Across All Segments In 1Q24

• Hyphens Pharma (SGX:1J5)'s revenue for 1Q24 has increased by 44.4% y-o-y to S$48.0m, driven by improvement in sales from all segments compared to a year ago which was heavily affected by supply chain disruptions.
• - Read this at SGinvestors.io -

1Q24 results were within our expectations.

• Correspondingly, gross profit improved by 32.8% y-o-y to S$17.4m. However, Hyphens Pharma's gross margin decreased to 36.3% in 1Q24 from 39.5% in 1Q23 due to ongoing cost pressures and a higher sales mix of lower margin products.
• Net profit after tax surged by 97.6% y-o-y to S$2.7m, in line with the higher revenue. Consequently, gross profit fell 7.0% q-o-q and net profit decreased by 6.6% q-o-q.
• - Read this at SGinvestors.io -

Optimism Intact

• Our positive outlook remains unchanged, and we expect Hyphens Pharma's announced initiatives to proceed as planned.
  • Read more at SGinvestors.io.
  
  
  
  
  
  
  Daniel Ng Ming Ci SAC Capital Research | Matthias Chan SAC Capital | https://www.saccapital.com.sg/ 2024-05-16 SGinvestors.io
  
  

  ---

  
  

  Read also SAC's most recent report:
  2024-08-22 Hyphens Pharma International - Commendable Growth Amid Economic Headwinds.

  Price targets by 2 other brokers at Hyphens Pharma Target Prices.

  Listing of research reports at Hyphens Pharma Analyst Reports.

  Relevant links:
  Hyphens Pharma Share Price History,
  Hyphens Pharma Announcements,
  Hyphens Pharma Dividends & Corporate Actions,
  Hyphens Pharma News Articles